Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) will hold its 3Q20 earnings conference call with the financial community on 29th October 2020 at 8:00 AM Eastern Time.
The conference call will be webcast live on Internet at www.constellationpharma.com
Earnings Expectation
Constellation Pharmaceuticals, Inc. is reporting third quarter financial results on Thursday 29th October 2020, before market open.
According to analysts surveyed by Thomson Reuters, CNST is expected to report 3Q20 loss of $ 0.68 per share. For the full year, analysts anticipate loss of $ 2.73 per share bottom line.
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The companys lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors.
